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Abstract Comparison of crystallographic structures of human
growth hormone, either bound to the prolactin receptor or free of
receptors, reveals that human growth hormone binding to the
prolactin receptor at site 1 is associated with a structural change
in human growth hormone that influences the organization of
residues which constitute site 2. We have identified Tyr164 as a
residue that is critical for the propagation of this structural
rearrangement. Tyr164 is a structural epitope for site 1 and is
distal to site 2. Mutation of Tyr164 to glutamic acid (Y164E)
does not affect the somatotrophic activity, absorption or
fluorescence spectra or binding to the human prolactin receptor
when compared to wild-type human growth hormone, indicating
the subtle effects of the mutation. Lactogenic assays using
extended concentrations of Y164E human growth hormone
produce dose-response curves that are characterized by a right-
shifted agonist phase and an unchanged antagonist phase when
compared to wild-type human growth hormone. These results
indicate that Tyr164 is required for the lactogenic activity of
human growth hormone and that mutation to glutamic acid
disrupts the lactogenic function of site 2.
z 1999 Federation of European Biochemical Societies.
1. Introduction
Human growth hormone (hGH) is a ligand of the subclass
1 of the hematopoietic receptor superfamily [1] and is able to
bind and activate both somatotrophic and lactogenic recep-
tors [2]. hGH binds two receptors in a sequential order on two
distinct faces of the ligand (sites 1 and 2) [3]. hGH is an
important recombinant protein marketed for treatment of
some types of impaired stature and is recognized as having
bene¢cial e¡ects in elderly patients with reduced hGH blood
concentrations [4].
X-ray crystallographic structures are available for receptor-
free hGH (Protein Data Base number 1HGU), hGH bound to
one extracellular domain of the human prolactin receptor [5]
and hGH bound to either one (PDB number 1A22 and
1HWH)[6,7] or two (PDB number 3HHR and 1HWG)[7,8]
extracellular domains of the hGH receptor. Comparison of
these structures reveals that hGH undergoes structural
changes associated with receptor binding and that are unique
to binding either GH or prolactin receptors. From the evi-
dence available, the structural changes in hGH are coincident
with binding the ¢rst receptor at site 1 of hGH. The mecha-
nism by which site 1 binding initiates these conformation
changes and their functional importance are unknown.
Mutagenic studies o¡er a method to identify the residues
which are functionally important [9]. Mutagenesis may iden-
tify members of the motif that transmit binding-induced struc-
tural changes to portions of the protein which are distal to site
1. Mutation of residues within a motif which propagates a
conformation change may alter the conformation change
and change dose-response curves in a predictable fashion.
Such changes may be unique from those observed by muta-
tions within the functional epitopes of sites 1 or 2.
Several papers have described the e¡ects on biological and
binding assays for ligands that have been mutated within the
functional epitopes contained within sites 1 or 2 [10,11]. Hor-
mones that stimulate target cells through receptor dimeriza-
tion mechanisms display dose-response curves in biological
assays that are bell-shaped where ligands function as agonists
at low concentrations and antagonists at higher concentra-
tions. The characteristics of extended dose-response curves
di¡erentiate the e¡ects of mutations within sites 1 and 2.
Mutations of the functional epitopes within site 1 either in-
crease or decrease the ligand receptor a⁄nity at this site and
shift both agonist and antagonist phases of the dose-response
curve to the left or right, respectively. In contrast, mutations
within the functional epitopes of site 2 are re£ected in mod-
ulation of the maximal biological activity. Mutations outside
the functional epitopes of sites 1 or 2 may or may not a¡ect
dose-response curves. Interpretation of the e¡ects of muta-
tions which lay outside of the functional epitopes of sites 1
or 2 have not been described for biological or binding assays.
We have produced mutations in hGH that are either within
(G120R) or external (Y164E) to the functional epitopes of site
2. The data from biological and binding studies demonstrate a
previously unrecognized e¡ect on dose-response curves which
supports the hypothesis that selected residues distal from the
second receptor binding site a¡ect the ability of site 2 of hGH
to activate the human prolactin receptor.
2. Materials and methods
2.1. Plasmids and bacterial strains
A f1 origin of replication was inserted at a unique Cla I site in pT7-
7 (kindly provided by S. Tabor, Harvard Medial School, Boston, MA,
USA). The positive strand pT7-7 phagemid was used for cloning,
production of ssDNA and expression of hGH. Escherichia coli strains
DH5K, RZ1032 (dut3 and ung3) and BL21(DE3) were used for clon-
ing, production of uradin-substituted ssDNA and protein expression,
respectively. The pT7-7f(+) phagemid for the expression of wild-type
hGH has previously been described [12,13].
2.2. Site-directed mutagenesis
In vitro mutagenesis was performed by the method of Kunkel [14].
Primers were designed to produce the desired mutations and either
add or delete a translationally silent restriction endonuclease site to
allow rapid selection of potential mutants. Clones identi¢ed by restric-
tion digests were completely sequenced to con¢rm the presence of the
desired mutation(s).
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2.3. Expression, puri¢cation and characterization of hGHs
Puri¢ed phagemids containing wild-type, G120R or Y164E hGH
DNAs were transformed into BL21(DE3) cells and expressed and
puri¢ed as previously described [12,13]. Proteins were evaluated for
size and purity by 15% SDS-PAGE under non-reducing or reducing
conditions. Absorption and £uorescence spectra were collected at
20‡C in 10 mM Tris pH 8.2, 150 mM NaCl.
2.4. FDC-P1 lactogenic assay
FDC-P1 cells containing the human prolactin receptor were a gift
from Genentech (South San Francisco, CA, USA). Cells were main-
tained in RPMI 1640 containing 10 WM 2-mercaptoethanol, 1 nM
wild-type hGH and 10% fetal calf serum [15]. Log phase cells were
collected and washed three times with non-supplemented RPMI 1640.
Washed cells were suspended in media devoid of wild-type hGH and
phenol red but supplemented with 10% horse serum. Cells were main-
tained under these conditions for 24 h immediately prior to the assay.
Recombinant hGH stock concentrations were determined by the bi-
cinchoninic acid/copper sulfate assay [16]. Hormone stocks were di-
luted with phenol red-free media to the desired concentrations and
added to 96 well plates in triplicate wells. Each well contained 15 000
FDC-P1 cells in a total volume of 100 Wl. Plates were gently agitated
and then incubated at 37‡C in a 5% CO2/95% air atmosphere for 48 h.
Hormone-induced proliferation of the cells was assessed by a vital dye
method with the addition of 10 Wl of Alamar blue (Accumed Interna-
tional, West Lake, OH, USA) per well, followed by a 4 h incubation.
The oxidation-reduction of Alamar blue was evaluated at 570 and 600
nm. These values were used to calculate the percentage reduction of
the dye, which is highly correlated with the cell number (r2s 0.99).
The values obtained from dose-response studies were used to calculate
ED50s for the agonist phases by a four parameter ¢t method [17].
ID50s for the antagonist phases were estimated from plots of the
dose-response curves. In instances where the antagonist phase of the
dose-response curve reached the x-axis, values determined by the four
parameter ¢t method and graphical estimation were similar. Further
extension of the dose-response curves were not possible due to the
limited solubility of hGH.
2.5. FDC-P1 somatotrophic assay
Somatotrophic activities of each hormone preparation were deter-
mined with FDC-P1 cells transfected with the hGH receptor [18] as
described by Peterson and Brooks [12]. These cells were a gift from
Genentech (South San Francisco, CA, USA).
2.6. Lactogen receptor binding assays
hGH was iodinated using Iodogen (Pierce Chemical, Rockford, IL,
USA) and carrier-free [125I]iodine to a speci¢c activity of 45 WCi/Wg.
Binding reactions contained membranes from 2U106 cells in 700 Wl of
RPMI 1640 medium supplemented with 25 mM HEPES at pH 7.4,
0.5% bovine albumin, 5 mM MgCl2, 1 mM phenylmethylsulfonyl
£uoride, 10 Wg/ml aprotinin, approximately 1 ng of [125I]hGH and
various concentration of recombinant hGHs. Assays were supple-
mented with 1 mM ZnSO4. Incubations were run for approximately
20 h at room temperature. Membranes were collected by centrifuga-
tion and membrane-associated [125I]hGH was measured. Data from
competition studies were used to calculate relative a⁄nities by the
method of Scatchard [19].
3. Results
3.1. Characterization of proteins
DNA sequence analysis of the pT7-7 phagemids showed
sequences to be identical to those previously reported for
hGH [20] or to contain the changes directed by mutagenesis.
Yields of the puri¢ed proteins were greater than 20 mg/l fer-
mentation. SDS-containing gel electrophoresis performed
under reducing conditions (Fig. 1) revealed each hGH to be
greater than 95% pure and have a molecular weight similar to
hGH isolated from pituitaries. Electrophoresis in the absence
of 2-mercaptoethanol showed that the proteins ran with a
similar Mr, indicating that the proteins folded with the same
pattern of disul¢de bond which produced molecules with sim-
ilar hydrodynamic radii [13].
Absorption spectra of Y164E and wild-type hGH overlay
each other (Fig. 2), indicating that the tertiary structures of
these proteins are very similar. In contrast, the spectrum of
G120R hGH showed an increased absorption in the 250 and
340 nm regions. We interpret these results to indicate that the
G120R mutation increases the aggregation of this protein at
FM concentrations. The £uorescence spectra of the three pro-
teins were similar, indicating that the environment of the the
Trp and Tyr residues were unchanged by either of these mu-
tations (Fig. 3).
In two trials, the somatotrophic activities of wild-type and
Y164E hGHs produced similar ED50s of 0.36 and 0.42 nM,
respectively. G120R hGH displayed a somatotrophic ED50 of
2.31 nM. Both wild-type and Y164E hGHs had equivalent
maximal activities, but G120R hGH displayed approximately
half the maximal activity of wild-type hGH. These results are
Fig. 1. 15% SDS-PAGE of recombinant hGHs. Wild-type (lanes 1
and 5), G120R (lanes 2 and 6) and Y164E (lanes 3 and 7) hGHs
were prepared in the presence (lanes 1^3) or absence (lanes 5^7) of
1% 2-mercaptoethanol. Lane 4: reduced molecular weight markers
in kDa. Fig. 1 is a digital image of the Coomassie-stained gel.
Fig. 2. Absorption spectra of recombinant hGHs. Wild-type,
G120R and Y164E hGHs were prepared at 20 FM in 10 mM Tris
pH 8.2, 150 mM NaCl. Spectra were collected at 20‡C.
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consistent with previous reports in the literature which de-
scribe Gly120 as a functional epitope of site 2 [6,15].
3.2. Activation of the lactogenic actions by hGH
Wild-type, G120R and Y164E hGHs were used to stimulate
the growth of FDC-P1 cells that were transfected with the
human prolactin receptor. Extended dose-response curves
were performed to describe both the agonist and antagonist
phases. FDC-P1 lactogenic assays displayed an average coef-
¢cient of variation of 28%. Based on our experience with this
assay, a greater than 2^3-fold change in agonist or antagonist
response was considered to be a signi¢cant change.
The wild-type hGH concentration required to elicit a half
maximal agonist response (ED50) was 12.1 nM (Fig. 4, Table
1), with the concentration required to antagonize the maximal
response by 50% (ID50) was W5 750 nM.
Mutation of Gly120 to arginine did not signi¢cantly e¡ect
either the ED50 (19.5 nM) or ID50 (W3 000 nM) of hGH. But
the maximal response was reduced to 21% of that induced by
wild-type hGH.
In contrast, the concentration of Y164E hGH required to
induce the agonist phase of the dose response curves was
28-fold greater (ED50 = 338.8 nM) than that for wild-type
hGH, while the ID50 (W10 000 nM) was not changed by
this mutation, remaining within 2-fold of the ID50 for wild-
type hGH. The maximal response was reduced to 72% of the
value for wild-type hGH. The ratio of ID50/ED50 for wild-
type hGH was 475, while the ratio for Y164E hGH had nar-
rowed to 29.
The shapes and positions of the bell-shaped dose-response
curves were a¡ected by mutations. Wild-type and G120R
hGHs had superimposed dose-response curves when they
were normalized for the maximal response. The ED50 and
ID50 for these two proteins di¡ered by several hundred-fold.
Y164E hGH displayed a dose-response curve where the ED50
and ID50 were more closely spaced di¡ering by only a 29-fold.
The agonist phase of the dose-response curve was shifted right
from wild-type hGH, but the antagonist phases were coinci-
dent.
3.3. Prolactin receptor binding by hGH mutants
Competitive binding studies were performed with 125I-la-
belled wild-type hGH and increasing concentrations of each
hGH. Scatchard analysis of wild-type, G120R or Y164E hGH
competitions revealed similar a⁄nities, between 0.047 and
0.070 nM (Table 1). These competition studies represent
measurements of the relative a⁄nities of the competing pro-
tein for the lactogenic receptors.
4. Discussion
Tyr164 is distal to site 2 of hGH and has a pattern of
agonist and antagonist activities that are distinct from both
wild-type and G120R hGHs. The e¡ects of the Y164E muta-
tion are to right shift the agonist phase of the dose-response
curve but not alter the antagonist phase. To date, we have
observed similar changes in the dose-response curves of three
other mutations that are external to both sites 1 and 2 (Duda,
Peterson and Brooks, in preparation)
The ED50 of dose-response curves represent the ¢nal cellu-
lar response to increasing hormone concentrations. This re-
sponse is determined by numerous coupled and complex proc-
esses including the relative a⁄nities of sites 1 and 2 for
receptors, the density of receptors in the plasma membrane
of the target cells and numerous reactions within the target
cells. The cellular portion of this system, in our case the FDC-
P1 lactogenic assay, is a constant. Thus, only the ligand a⁄n-
ities for receptors at sites 1 and 2 are variables in this process.
Mutations of the ligand that e¡ect the agonist phase of the
dose-response curve must in£uence binding at either site 1,
site 2 or both sites. In contrast, mutations of the ligand that
only e¡ect the antagonist phase of the dose-response curve
Fig. 3. Fluorescence spectra of recombinant hGHs. Wild-type,
G120R and Y164E hGHs were prepared at 18 FM in 10 mM Tris
pH 8.2, 150 mM NaCl. Spectra were collected at 20‡C with an exci-
tation wavelength of 280 nm.
Fig. 4. FDC-P1 cells transfected with the human prolactin receptor
and stimulated by recombinant hGHs. FDC-P1 cells were assayed
as described in Section 2 and the relative hGH-induced increase in
cell number was followed with a vital dye method. All three curves
were run in the same experiment.
Table 1
Agonist and antagonist activities and a⁄nities of hGHs
Hormone ED50 ID50 Kd
Wild-type hGH 12.1 nM W5 750 nM 0.047 nM
G120R hGH 19.5 nM W3 000 nM 0.047 nM
Y164E hGH 338.8 nM W10 000 nM 0.070 nM
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must only e¡ect site 1, because in receptor dimerization mod-
els, antagonist activities are determined only by the ligand and
receptor concentrations and their a⁄nity at site 1. Mutations
of hGH within the functional epitopes of sites 1 or 2 demon-
strate the validity of this reasoning. When functional epitopes
within site 1 of hGH are mutated, both phases of the dose
response curve are shifted in parallel, similarly, when func-
tional epitopes within site 2 are mutated, the maximal re-
sponse is limited [10,11].
Therefore, mutations external of the functional epitopes of
sites 1 or 2, which shift the agonist phase of the dose response
curve but do not a¡ect the ID50 of the antagonist phase, must
in£uence the function of site 2. Y164E hGH ¢lls these criteria
(Fig. 4 and Table 1) with a 29-fold reduction in the ED50 of
the agonist phase and no measurable change (less than 2-fold)
in the ID50 of the antagonist phase when compared to wild-
type hGH. Thus, the Y164E mutation produces these e¡ects
by impairing the function of site 2.
Tyr164 is located on the opposite end of hGH from site 2.
Tyr164 is a structural, but not a functional, epitope of site 1
[3,5]. Our mutagenic data support the conclusion that Tyr164
is not a site 1 functional epitope because this mutation a¡ects
neither the a⁄nity for the hPRL receptor (Table 1) nor the
antagonist phase of the dose-response curve (Fig. 4). These
characteristics would be a¡ected if Tyr164 was within a func-
tional epitope of site 1. Further, this mutation has little or no
in£uence on somatotropic activities of hGH (Table 1) or
structural characteristics determined by spectroscopy (Fig. 2
and 3). Thus, the Y164E mutation is benign to the overall
structure of hGH.
We interpret our data to suggest that Tyr164 may be part of
a motif that undergoes the change of conformation induced
by hGH binding to a lactogenic receptor at site 1 and docu-
mented by crystallographic structures (PDB number 1HGU)
[5]. We suggest that disruption of this motif by mutagenesis
reduces the e¡ective transmission of the conformation change
to site 2. Further work is in progress to identify the remaining
residues that constitute this motif.
Fuh et al. [15] have previously used the FDC-P1 hPRL
receptor assay to demonstrate the e¡ects of the G120R muta-
tion on hGH. The same general results were observed with
G120R hGH having a severely reduced maximal activity. Sev-
eral di¡erences were also apparent. First, the activity of
G120R hGH was reduced by approximately 80% in our
work, while Fuh and colleagues showed a more substantial
reduction in activity. Second, Fuh and colleagues’ ED50s were
approximately an order of magnitude smaller and ID50s were
approximately an order of magnitude larger than our values.
Although both studies were performed in FDC-P1 cells that
were transfected with the 591 residue hPRL receptor, the
number of receptors per cell was probably greater in the
work by Fuh et al. Such a di¡erence in receptor number
would explain the di¡erences in both agonist and antagonist
phases of the dose-response curves for wild-type hGH. When
either Fuh and colleagues [15] performed these same studies in
Nb2 cells [21], they observed similar trends but with lower
ED50s and higher ID50s. These results are consistent with
the high number of prolactin receptors found in Nb2 cells.
These data are quite di¡erent than those of Dattani et al. [22]
who performed Nb2 assays. Dattani and colleagues observed
similar maximal activities with either wild-type or G120R
hGH, but a higher ED50 and lower ID50 when the G120R
hGH was compared to wild-type hGH. These shifts in the
dose-response curves are not expected if the G120R mutation
a¡ects site 2 and were not observed in our studies in FDC-P1
cells.
Mutations resulting in structural changes of proteins may
a¡ect functional properties and will provide clues to structure/
function relationships of the protein. Crystallographic struc-
tures of hGH are available and useful when interpreting the
e¡ects of structural modi¢cations generated by mutagenesis.
The presence of a tyrosine at position 164 appears to promote
the prolactin receptor binding at site 2 which may operate
through a receptor binding-induced conformation change. Re-
placement of this hydrophobic residue with hydrophilic gluta-
mic acid disrupts the arrangement of a hydrophobic pocket
whose formation is promoted by binding of the prolactin
receptor at site 1. Formation of this hydrophobic pocket is
associated with rearrangement of local residues which are el-
ements for the conformation change associated with restruc-
turing the residues of hGH that comprise site 2. We have
previously published mutagenic studies of Phe44 in hGH
[12]. Phe44 is required for the lactogenic activities of hGH
and articulates with Tyr164 upon ligand binding to the prolac-
tin receptor to form a hydrophobic cluster. These residues
may form a motif that regulate the site 2 function via site 1
binding.
In summary, we have identi¢ed by site-directed mutagenesis
a residue that, despite being close to site 1 and distal to site 2,
in£uences the ability of site 2 to function. Further, we have
characterized the functional e¡ects in lactogenic assays ob-
tained by mutation of a hydrophilic residue within the struc-
ture of hGH. We believe this pattern of altered function,
characterized by a right-shifted agonist action and unchanged
antagonist actions, will be observed when elements of motifs
transmitting binding-induced conformation changes are al-
tered by mutation.
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